12 May, 2025AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
26 February, 2025NanoPhoria Bioscience awarded €17.5 M from European Innovation Council’s accelerator program
11 December, 2024Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
3 December, 2024AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
28 October, 2024AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)